Actively Recruiting
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Led by M.D. Anderson Cancer Center · Updated on 2025-11-19
30
Participants Needed
1
Research Sites
372 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To learn about the effects of paclitaxel and gastrectomy (surgery to remove all or part of the stomach) on improving outcomes in patients with gastric cancer.
CONDITIONS
Official Title
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years and above with no upper age limit
- ECOG performance status of 2 or less (Karnofsky score 60% or higher)
- Cytologic or histologic confirmation of adenocarcinoma of the stomach or gastroesophageal junction
- Adequate kidney and bone marrow function: leukocytes ≥ 3,000/uL, absolute neutrophil count ≥ 1,500/uL, platelets ≥ 60,000/uL, serum creatinine ≤ 1.6 mg/dL
- Presence of distant metastatic disease limited to the peritoneum, shown by positive peritoneal cytology or carcinomatosis on laparoscopy or laparotomy
- Completion of preoperative systemic cytotoxic chemotherapy; targeted therapies and immunotherapies may continue
- Patients of any language (English or non-English speaking)
You will not qualify if you...
- Metastatic disease outside the peritoneum such as to liver, central nervous system, or lungs
- Active infections like pneumonia or wound infections that prevent treatment
- Women who are pregnant or of childbearing potential who do not agree to use adequate contraception and refrain from breastfeeding
- Men with reproductive potential who do not agree to use appropriate birth control methods
- Unstable angina or congestive heart failure of New York Heart Association Grade II or higher
- Cognitive impairment or inability to comply with study procedures
- Known life-threatening hypersensitivity to the chemotherapy used in this study
- Previous surgery preventing safe cytoreduction or placement of an intraperitoneal port
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
I
Iqra Rehman, RN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here